ELVN
Enliven Therapeutics, Inc.Healthcare·Biotechnology
$39.57
$2.4B market cap
Revenue
$0.0M
Free Cash Flow
$-35.1M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
2-Year Price History
$41.54+84.0%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -27.8 | -27.8 | -23.6 | -19.3 | -19.3 | -0.0 | 452.4 | 0.3 | 62.8 | -78.9% | -- | -- |
| Act | 2025-Q4 | 0.0 | -34.2 | -34.3 | -29.7 | -15.8 | -15.8 | -0.0 | 462.6 | 0.4 | 56.7 | -91.6% | -- | -- |
Valuation & Metrics
Market Stats
Price$39.57
Market Cap$2.4B
Enterprise Value$2.0B
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-1.5%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-53.3M
Free Cash Flow$-35.1M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-85.2%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares5.3M
Days to Cover6.9
Change (vs Prior)-1.9%
Need at least 2 settlement dates for chart
Employees
Headcount62
Revenue / Employee$0
Gross Profit / Employee$-968
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
78.4%(+45.8% YoY)
151 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
14.8%(+9.5% YoY)
11 filers
Vanguard, iShares, SPDR
Market makers
0.5%(+0.5% YoY)
6 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | $312M | $21.90 | +$0 | +$0 | -8.3% | $4.38B |
| FMR LLC | $268M | $19.82 | −$10.9M | +$8.6M | -0.0% | $1.89T |
| Polar Capital Holdings Plc | $199M | $26.77 | +$60.8M | +$106M | +1.5% | $22.76B |
| BlackRock, Inc.Passive | $144M | $24.72 | +$2.8M | +$26.9M | -0.2% | $5.69T |
| Commodore Capital LP | $128M | $19.63 | −$55.6M | −$54.9M | -0.1% | $1.73B |
| Vestal Point Capital, LP | $127M | $16.91 | −$22.7M | +$127M | -0.4% | $3.58B |
| Bellevue Group AG | $91.0M | $39.20 | +$91.0M | +$91.0M | -4.3% | $4.20B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $85.0M | $39.20 | +$85.0M | +$85.0M | — | $4.04T |
| Fairmount Funds Management LLC | $72.7M | $20.31 | −$72.7M | −$52.8M | +4.6% | $1.38B |
| CITADEL ADVISORS LLC | $68.4M | $22.61 | +$12.5M | +$24.3M | -0.4% | $138.22B |
| VR Adviser, LLC | $67.7M | $19.26 | −$58.8M | −$90.2M | -1.8% | $2.68B |
| Novo Holdings A/S | $50.2M | $19.99 | −$7.8M | +$50.2M | -3.3% | $1.23B |
| STATE STREET CORPPassive | $42.8M | $21.37 | +$1.5M | +$12.2M | -0.2% | $2.89T |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $41.8M | $21.28 | +$694K | +$9.7M | +2.3% | $1.61T |
| Pictet Asset Management Holding SA | $36.4M | $22.49 | −$14.6M | −$1.5M | -1.1% | $94.52B |
| BAKER BROS. ADVISORS LP | $35.5M | $32.34 | +$24.8M | +$31.0M | -0.5% | $16.13B |
| Rock Springs Capital Management LP | $32.4M | $18.80 | +$1.1M | +$14.1M | -2.0% | $1.65B |
| Siren, L.L.C. | $29.3M | $39.20 | +$29.3M | +$29.3M | +6.1% | $3.61B |
| DIMENSIONAL FUND ADVISORS LPPassive | $26.7M | $26.47 | +$11.1M | +$26.7M | -0.4% | $480.92B |
| First Turn Management, LLC | $24.5M | $22.72 | −$6.3M | +$3.5M | +0.1% | $854M |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-0.85%
avg per quarter
Holders (ex-self)
-0.92%
excl. this stock
Buyers (this Q)
+0.15%
118 buyers · $1.00B in
Sellers (this Q)
+0.66%
40 sellers · $-0.36B out
alpha coverage: 94% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-3.4%
how holders react when this stock falls
On quiet Qs
-9.5%
−10% to +10% baseline
On rallies (+10%+)
-5.1%
how they react when this stock rises
Holders' portfolio flow this Q
-0.1%
outflows — trims may be forced
Sellers' portfolio flow this Q
+1.9%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-3.9%
Holder mid (any stock)
-3.5%
Holder rally (any stock)
-7.3%
Biggest decreases this quarter
Fairmount Funds Management LLC−$72.7Mα+4.6VR Adviser, LLC−$58.8Mα-1.8Commodore Capital LP−$55.6Mα-0.1Point72 Asset Management, L.P.exited−$23.2MVestal Point Capital, LP−$22.7Mα-0.4Capital Research Global Investorsexited−$20.1MBlackstone Group L.P.exited−$14.7MPictet Asset Management Holding SA−$14.6Mα-1.15AM Venture Management, LLCexited−$11.9MFMR LLC−$10.9Mα-0.0
New buyers this quarter
Top-5 holders · 43.3%
ORBIMED ADVISORS LLC--
FMR LLC--
Polar Capital Holdings Plc--
BlackRock, Inc.--
Commodore Capital LP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
ORBIMED ADVISORS LLC8.0MFMR LLC6.8MPolar Capital Holdings Plc5.1MCommodore Capital LP3.3MVestal Point Capital, LP3.3M5AM Venture Management, LLC—VR Adviser, LLC1.7MBellevue Group AG2.3MFairmount Funds Management LLC1.9MCITADEL ADVISORS LLC1.7M
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| JBIO | Jade Biosciences, Inc. | 3 | 124.94× |
| DMRA | Galecto, Inc. | 3 | 124.94× |
| XENE | Xenon Pharmaceuticals Inc. | 6 | 107.09× |
| AGIO | Agios Pharmaceuticals, Inc. | 3 | 102.22× |
| DNTH | Dianthus Therapeutics, Inc. | 7 | 100.91× |
| NUVL | Nuvalent, Inc. | 4 | 99.95× |
| SRRK | Scholar Rock Holding Corporation | 5 | 98.64× |
| ARGX | argenx SE | 5 | 93.71× |
| EYPT | EyePoint Pharmaceuticals, Inc. | 3 | 93.71× |
| VRDN | Viridian Therapeutics, Inc. | 4 | 88.19× |
| CGON | CG Oncology, Inc. Common stock | 4 | 88.19× |
| GPCR | Structure Therapeutics Inc. | 4 | 83.29× |
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (2 analysts)$69.507560.0%
Last Year (3 analysts)$63.676090.0%
Current Price$39.57
Analyst Ratings
7
Buy: 7Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$15.48M
54 txns · 6 insiders · 609,095 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-18 | SELL | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | 5,000 | $39.79 | $199K | $995K |
| 2026-04-17 | SELL | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | 5,000 | $47.67 | $238K | $1.19M |
| 2026-03-25 | SELL | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | 40,000 | $35.10 | $1.40M | $878K |
| 2026-03-17 | SELL | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | 5,000 | $27.76 | $139K | $694K |
| 2026-03-10 | SELL | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | 10,129 | $30.19 | $306K | $755K |
| 2026-03-09 | SELL | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | 29,871 | $30.02 | $897K | $751K |
| 2026-03-06 | SELL | Hohl Benjamin | officer: CHIEF FINANCIAL OFFICER | 10,000 | $29.58 | $296K | $1.51M |
| 2026-02-17 | SELL | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | 45,000 | $26.17 | $1.18M | $654K |
| 2026-02-17 | SELL | Heyman Richard A. | director | 1,230 | $26.18 | $32K | $593K |
| 2026-02-06 | SELL | Lyssikatos Joseph P | officer: CHIEF SCIENTIFIC OFFICER | 5,000 | $29.04 | $145K | $21.50M |
| 2026-01-20 | SELL | Heyman Richard A. | director | 1,230 | $26.75 | $33K | $639K |
| 2026-01-20 | SELL | Lyssikatos Joseph P | officer: CHIEF SCIENTIFIC OFFICER | 20,000 | $26.75 | $535K | $19.94M |
| 2026-01-09 | SELL | Patel Anish | officer: CHIEF OPERATING OFFICER | 48,300 | $27.99 | $1.35M | $6.02M |
| 2026-01-09 | SELL | Lyssikatos Joseph P | officer: CHIEF SCIENTIFIC OFFICER | 91,198 | $27.22 | $2.48M | $20.83M |
| 2026-01-09 | SELL | Heyman Richard A. | director | 4,285 | $25.00 | $107K | $628K |
| 2026-01-08 | SELL | Heyman Richard A. | director | 9,635 | $25.03 | $241K | $639K |
| 2026-01-08 | SELL | Lyssikatos Joseph P | officer: CHIEF SCIENTIFIC OFFICER | 41,302 | $24.05 | $993K | $20.60M |
| 2025-12-19 | SELL | Lyssikatos Joseph P | officer: CHIEF SCIENTIFIC OFFICER | 5,000 | $16.84 | $84K | $15.12M |
| 2025-12-08 | SELL | Patel Anish | officer: CHIEF OPERATING OFFICER | 6,663 | $21.02 | $140K | $5.54M |
| 2025-11-19 | SELL | Lyssikatos Joseph P | officer: CHIEF SCIENTIFIC OFFICER | 12,500 | $22.33 | $279K | $20.16M |
Order Flow (FINRA, ~3w lag)
12.3%retail-9.4pp
38.3%dark+8.5pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Enliven Therapeutics: A Cash-Rich Fortress with Revolving Executive Doors
Overall Risk
5/10
Fraud
2/10
Dilution
9/10
Insolvency
3/10
Earnings Overstated
2/10
Hidden Liabilities
3/10
Legal
2/10
Audit Warnings
4/10
Hidden Upside
6/10
Contextually Acceptable
7/10